C.R. Bard (NYSE:BCR) today released what could be its final quarterly report as a stand-alone company, posting third quarter EPS that beat the Street’s expectations but sales that fell just short. The Murray Hill, N.J.-based company posted profits of $94.1 million, or $1.25 per share, on sales of $989.8 million for the 3 months ended September […]
C.R. Bard
Becton Dickinson wins conditional EU approval for Bard buy
Becton Dickinson & Co. (NYSE:BDX) has secured anti trust approval in the European Union for its $24 billion acquisition of C.R. Bard (NYSE:BCR) after selling 2 subsidiaries to remove concerns over competition, according to a Reuters report. Concessions included a pledge from BD to sell its global core needle biopsy device division and an in-development tissue marker […]
BD offers EU concessions in $24B Bard acquisition
Becton Dickinson (NYSE:BDX) has offered concessions to address certain EU antitrust concerns as it looks to acquire C.R. Bard (NYSE:BCR) in a $24 billion deal, according to the European Commission. Franklin Lakes, N.J.-based Becton Dickinson submitted the concessions yesterday, according to a filing on the EU competition authority, but did not provide any details on the submission. The Commission […]
W.L. Gore loses bid to toss verdict in stent graft patent loss to C.R. Bard
A Delaware federal judge this week dismissed an attempt from W.L. Gore & Associates to clear a jury finding from March which ruled that 1 of its stent patents was invalid in an ongoing patent spat with C.R. Bard (NYSE:BCR), Law360 reports. U.S. District Judge Leonard Stark denied 3 motions for judgement, including 2 motions arguing […]
BD extends Bard tender again
Becton Dickinson & Co. (NYSE:BDX) once again extended its tender offer for up to $1.1 billion in outstanding C. R. Bard (NYSE:BCR) notes from August 29 to Sept. 27 ahead of their $24 billion merger. The $317-per-share deal, announced last April, is expected to close during the fourth quarter. Bard shareholders approved the transaction earlier this month. BD […]
Bard lands new indication for its drug-coated balloon
C. R. Bard(NYSE:BCR) said today that its Lutonix 035 drug-coated balloon PTA catheter won premarket approval from the FDA and is available in the U.S. The company’s Lutonix 035 device is the first drug-coated balloon approved in end-stage renal disease patients with stenotic lesions in dialysis arteriovenous fistulae. Bard’s DCB is also approved to treat […]
Bard shareholders approve $24B merger with BD
Shareholders in C.R. Bard (NYSE:BCR) yesterday overwhelmingly approved a $24 billion merger with Becton Dickinson & Co. (NYSE:BDX) The $317-per-share deal, which was announced last April, is expected to close during the fourth quarter, the companies said. Consummation of the deal is still waiting on anti-trust approvals, including by the U.S. Federal Trade Commission. In June, the […]
C.R. Bard faces DoJ FCA probe, posts Q2 earnings
C.R. Bard (NYSE:BCR) said today that the US Department of Justice is investigating possible False Claims Act violations related to the sales and marketing of its FloChec and QuantaFlow devices, alongside releasing Q2 earnings which topped expectations on The Street. The Murray Hill, N.J.-based company said this month it was served with a “civil investigative demand” […]
Lumicell taps ex-Accuray COO Londy as CEO | Personnel Moves July 18, 2017
Lumicell said last week it tapped former Accuray (NSDQ:ARAY) chief operating officer Kelly Londy as its new chief exec, with founder W. Lee moving to take the role of prez & chief scientific officer. Prior to holding the COO position at Accuray, Londy has held leadership positions at GE Healthcare (NYSE:GE) and Royal Philips (NYSE:PHG), Lumicell said. “We are […]
Zimmer Biomet prez, CEO Dvorak unexpectedly resigns | Personnel Moves, July 12, 2017
Zimmer Biomet (NYSE:ZBH) said late yesterday its prez and CEO David Dvorak has resigned from his position at the head of the company, effective immediately, to be replaced on an interim basis by senior VP and CFO Daniel Florin until a permanent successor is named. The Warsaw, Ind.-based company said it is retaining “a leading executive search […]
BD extends Bard note exchange offering again
Becton Dickinson (NYSE:BDX) said today is once again extending its exchange offering for up to $1.1 billion in outstanding C. R. Bard (NYSE:BCR) notes from July 3 to August 1. The company is offering exchanges for approximately $500 million for 4.4% Bard note due 2021, $500 million for 3% notes due 2026 and $149.8 million in 6.7% notes […]
